Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cryoport, Inc. (NASDAQ: CYRX) has announced it will release its financial results for the first quarter ending March 31, 2023, on May 4, 2023, after U.S. market close. Alongside the earnings, a detailed review titled 'Cryoport First Quarter 2023 in Review' will be provided at 4:05 PM ET that day. The company will host a conference call at 5:00 PM ET to discuss the results, with a live webcast available on its investor relations page. The call requires a confirmation code for access and will be recorded for later replay. Cryoport specializes in temperature-controlled supply chain solutions for life sciences, with a global reach across Americas, EMEA, and APAC regions.
Cryoport, Inc. (NASDAQ: CYRX) has entered a three-year agreement with Boston IVF, enhancing its temperature-controlled supply chain solutions for reproductive materials across multiple U.S. states, including Massachusetts and New York. This collaboration aims to improve shipment efficiency and mitigate risks for patients relying on Boston IVF's services. Boston IVF, with over 150,000 successful births since 1986, will benefit from Cryoport's advanced technology and continuous monitoring. Both companies emphasize their commitment to exceptional patient care, marking a significant step in Cryoport's strategic growth in the reproductive healthcare sector.
Cryoport, Inc. (NASDAQ: CYRX) has entered a multi-year partnership with Inception Fertility, North America's leading provider of fertility services. This agreement enhances Cryoport's end-to-end supply chain solutions for shipping reproductive materials, ensuring better service and risk mitigation for families. Key features include the integration of Prelude's patient medical records with Cryoport's Cryoportal 2.0, streamlining data management related to shipments. Cryoport boasts a 99% success rate in reproductive medicine shipments in 2022, indicating a robust operational capability and positioning for future growth.
Cryoport (NASDAQ: CYRX) has confirmed it has no financial exposure or business relationship with Silicon Valley Bank as of March 13, 2023. The company does not hold any deposits, securities, or maintain accounts with Silicon Valley Bank or its affiliates. This statement aims to reassure investors following concerns surrounding the bank. Cryoport is a leader in temperature-controlled supply chain solutions for the life sciences sector, focusing on biopharmaceutical and cell and gene therapy markets. The company operates over 40 strategic locations globally, providing essential services to the biopharma/pharma, animal health, and reproductive medicine sectors.